

Aug 26, 2020

Publication and Data Sharing Policy (Part 13 of Phase 3 study of Vaccine Candidate for COVID-19)

 In 1 collection

DOI

<https://dx.doi.org/10.17504/protocols.io.bj6akrae>

Chris Ockenhouse¹, Chris Gast¹, Renee Holt¹, Jorge Flores¹

¹Center for Vaccine Innovation and Access, PATH (Washington D.C. and Seattle, Washington)

Coronavirus Method De...

PATH



Chris Ockenhouse

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.bj6akrae>

Protocol Citation: Chris Ockenhouse, Chris Gast, Renee Holt, Jorge Flores 2020. Publication and Data Sharing Policy (Part 13 of Phase 3 study of Vaccine Candidate for COVID-19). **protocols.io** <https://dx.doi.org/10.17504/protocols.io.bj6akrae>



License: This is an open access protocol distributed under the terms of the **[Creative Commons Attribution License](#)**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: August 22, 2020

Last Modified: August 26, 2020

Protocol Integer ID: 40866

Keywords: efficacy of vaccine candidate, study of vaccine candidate, different vaccine candidate, vaccine candidate, immunogenicity, efficacy, trial result, trial, controlled trial

Disclaimer

DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to **[protocols.io](#)** is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with **[protocols.io](#)**, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

Abstract

This is Part 13 of "Phase 3 randomized, double-blinded, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of **Vaccine Candidate** against COVID-19 in adults > 18 years of age"

This generic Phase 3 protocol was developed by the PATH team with support of the Bill and Melinda Gates Foundation. The aim of the collection is to share recommended best practices in designing and implementing a Phase 3 study of a COVID-19 vaccine candidate. As Phase 3 trials of different Vaccine Candidates proceed around the world, following the same protocols will ensure consistency and comparability of the Phase 3 trial results.

Please note that this is an evolving document, to be versioned and updated, based on community feedback and new data.

Attachments



Generic Phase 3 Prot...

557KB

Guidelines

The information generated in this study will be used by the **Sponsor** in connection with the development of the product and therefore may be disclosed to government regulatory agencies in various countries, as well as global public health organizations, such as the WHO. Study results will be made publicly available in compliance with the WHO mandated timeframe for public disclosure of results from clinical trials. The International Committee of Medical Journal Editors member journals have adopted a clinical trials registration policy as a condition for publication. The description of this study and the summary of results will be available on <http://www.ClinicalTrials.gov>. **Sponsor** or its designees will prepare a clinical study report according to ICH-E3 guidelines.

Sponsor/manufacturer recognizes the importance of communicating study findings and will therefore encourage publication in reputable scientific journals and presentation at seminars or conferences, while protecting the integrity of the ongoing trial. Any publication, lecture, or manuscripts of study findings by any individual involved with the study will be governed by the procedure outlined in the Clinical Trial Agreements by the relevant Parties. Within any presentation or publication, confidentiality of individual participants will be maintained, with identification by participant code number and initials, if applicable.

Any new information from this study or other studies that may affect the participant's health, welfare, or willingness to continue with the study will be given to the participant. The results of the study will be shared with the participants at their request. This will be through a letter, approved by the IRBs, detailing the information.

Additional Considerations:

Depending on the stage of development of the vaccine candidate, the existence of promising data from other COVID-19 vaccines, or the availability of an already licensed COVID-19 vaccine **Sponsor** may consider the use of a positive control (another COVID-19 vaccine) as a comparator for all three primary objectives of the Phase 3 trial, namely efficacy, safety, and immunogenicity. This would significantly impact the design of the study; for instance, if a correlate of protection has been identified for a licensed vaccine based on the same platform, there might not be a need to prove vaccine efficacy as a clinical endpoint if the immunogenicity of the unlicensed vaccine is qualitatively and quantitatively similar to that of the licensed vaccine.

It would be feasible and convenient to augment the current Phase 3 trial design to test, when applicable, the clinical consistency of the vaccine across three different lots, a requirement by many international regulatory agencies and the WHO PQ process. In that case, equal numbers of each of the three lots of vaccines will be randomly provided to sufficient recipients of each product to ensure statistical consistency in the immunogenicity outcome of the validated assay identified.

